Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature

被引：2
作者：
Baksh, Mizba [1 ]
Jiang, Liuyan [2 ]
Bhatia, Unnati [1 ]
Alegria, Victoria [1 ]
Sher, Taimur [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher [1 ,3 ,4 ]
Ailawadhi, Sikander [1 ,3 ]
Parrondo, Ricardo D. [1 ]
机构：
[1] Mayo Clin, Div Hematol Oncol, 4500 San Pablo Rd S,Mangurian Bldg,3rd Floor, Jacksonville, FL 32224 USA
[2] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA
[3] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA
[4] St Vincents Riverside, Hematol Oncol, Jacksonville, FL USA
来源：
CLINICAL CASE REPORTS | 2021年 / 9卷 / 12期
关键词：
IgM myeloma; lymphoplasmacytic lymphoma; lytic bone lesions; multiple myeloma; non-Hodgkin's lymphoma; Waldenstrom macroglobulinemia; SMALL LYMPHOCYTIC LYMPHOMA; IGM MULTIPLE-MYELOMA; WALDENSTROMS MACROGLOBULINEMIA; INTERNATIONAL WORKSHOP; TREATMENT RECOMMENDATIONS; OPEN-LABEL; RITUXIMAB; IBRUTINIB; DEXAMETHASONE; MULTICENTER;
D O I：
10.1002/ccr3.5181
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Waldenstrom macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.
引用
收藏
页数：8
相关论文
共 48 条
  • [1] Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1
    Anderson, G
    Gries, M
    Kurihara, N
    Honjo, T
    Anderson, J
    Donnenberg, V
    Donnenberg, A
    Ghobrial, I
    Mapara, MY
    Stirling, D
    Roodman, D
    Lentzsch, S
    [J]. BLOOD, 2006, 107 (08) : 3098 - 3105
  • [2] Multiple myeloma: Clinical review and diagnostic imaging
    Angtuaco, EJC
    Fassas, ABT
    Walker, R
    Sethi, R
    Barlogie, B
    [J]. RADIOLOGY, 2004, 231 (01) : 11 - 23
  • [3] 14q32 translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinernia
    Avet-Loiseau, H
    Garand, R
    Lodé, L
    Robillard, N
    Bataille, R
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (02) : 153 - 155
  • [4] Extramedullary Waldenstrom macroglobulinemia
    Banwait, Ranjit
    Aljawai, Yosra
    Cappuccio, Joseph
    McDiarmid, Serena
    Morgan, Elizabeth A.
    Leblebjian, Houry
    Roccaro, Aldo M.
    Laubach, Jacob
    Castillo, Jorge J.
    Paba-Prada, Claudia
    Treon, Steven
    Redd, Robert
    Weller, Edie
    Ghobrial, Irene M.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (02) : 100 - 104
  • [5] Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia in Waldenstrom's Macroglobulinemia
    Berentsen, Sigbjorn
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2009, 9 (01) : 110 - 112
  • [6] Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity
    Bonilla-Valentin, Fernando Javier
    Cerra, Javier
    Caceres-Perkins, William
    Alsina, Melissa
    [J]. CANCER CONTROL, 2018, 25 (01) : 1 - 4
  • [7] Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    Breitkreutz, I.
    Raab, M. S.
    Vallet, S.
    Hideshima, T.
    Raje, N.
    Mitsiades, C.
    Chauhan, D.
    Okawa, Y.
    Munshi, N. C.
    Richardson, P. G.
    Anderson, K. C.
    [J]. LEUKEMIA, 2008, 22 (10) : 1925 - 1932
  • [8] The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
    Campo, Elias
    Swerdlow, Steven H.
    Harris, Nancy L.
    Pileri, Stefano
    Stein, Harald
    Jaffe, Elaine S.
    [J]. BLOOD, 2011, 117 (19) : 5019 - 5032
  • [9] Castillo JJ, 2020, LANCET HAEMATOL, V7, pE827, DOI 10.1016/S2352-3026(20)30224-6
  • [10] What is new in the treatment of Waldenstrom macroglobulinemia?
    Castillo, Jorge J.
    Treon, Steven P.
    [J]. LEUKEMIA, 2019, 33 (11) : 2555 - 2562
12345